With rPFS as the primary endpoint, this trial has the potential to reshape treatment strategies for advanced prostate cancer, offering new hope for patients with limited options by exploring the efficacy of combining targeted radiation delivery to PSMA-expressing prostate cancer cells with immune-boosting effects [119]. Here, FOLH1 is linked to prostate carcinoma.